Expertise in
24
conditions

Dr. Peter Watson

Oncology
Kinston Community Health Center
313 Airport Rd, 
Kinston, NC 
Offers Telehealth
Expertise in
24
conditions
Kinston Community Health Center
313 Airport Rd, 
Kinston, NC 

Overview

Peter Watson is an Oncologist practicing medicine in Kinston, North Carolina.

Dr. Watson is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Angiosarcoma, Inflammatory Breast Cancer, Lung Cancer, and Small Cell Lung Cancer (SCLC).

He is actively involved in clinical research, co-authoring 3 peer reviewed articles and participating in 49 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in NC

Hospital Affiliations

Ecu Health Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

Kinston Community Health Center
313 Airport Rd, Kinston, NC 28504
Other Locations
Mobile Anesthesia Services PLLC
701 Doctors Dr Ste N, Kinston, NC 28501

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

49 Clinical Trials

DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: June 18, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 3
Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
Enrollment Status: Active_not_recruiting
Publish Date: June 18, 2026
Intervention Type: Drug
Study Drugs: Abiraterone acetate, Antiandrogen therapy, Cabazitaxel, Prednisone
Study Phase: Phase 2
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Enrollment Status: Active_not_recruiting
Publish Date: June 18, 2026
Intervention Type: Procedure, Drug, Other
Study Drug: Pazopanib Hydrochloride
Study Phase: Phase 3
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 3
A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)
A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Other, Drug, Radiation
Study Drugs: Carboplatin, Paclitaxel, Veliparib
Study Phase: Phase 1/Phase 2
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Other, Drug
Study Drugs: Temozolomide, Veliparib
Study Phase: Phase 2/Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
View 9 Less Clinical Trials

3 Total Publications

Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma.
Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 27, 2020
Similar Doctors
Expertise in
17
conditions
Dr. Jasmin Jo
Oncology
Expertise in
17
conditions
Dr. Jasmin Jo
Oncology
Referral may be required

Ecu Health Cancer Care-Eddie And Jo Allison Smith Tower At Ecu Health Medical Center

524 Moye Blvd, 
Greenville, NC 
 (23.8 miles away)
252-816-2273
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jasmin Jo is an Oncologist practicing medicine in Greenville, North Carolina. Dr. Jo is highly rated in 17 conditions, according to our data. Her clinical expertise encompasses Oligodendroglioma, Glioma, Astrocytoma, and Glioblastoma.

Expertise in
20
conditions
Expertise in
20
conditions
Referral may be required

Physicians East PA

1850 W Arlington Blvd, 
Greenville, NC 
 (23.0 miles away)
252-752-6101
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Diane Semer is an Oncologist practicing medicine in Greenville, North Carolina. Dr. Semer is highly rated in 20 conditions, according to our data. Her clinical expertise encompasses Virilizing Ovarian Tumor, Ovarian Carcinosarcoma, Malignant Mixed Mullerian Tumor, Hernia Surgery, and Ureteroscopy.

Expertise in
37
conditions
Dr. Misbah Qadir
Hematology | Oncology
Expertise in
37
conditions
Dr. Misbah Qadir
Hematology | Oncology
Referral may be required

ECU Health Cancer Care - Eddie And Jo Allison Smith Tower At ECU Health Medical Center

524 Moye Blvd, 
Greenville, NC 
 (23.8 miles away)
252-816-2273
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Misbah Qadir is a Hematologist and an Oncologist practicing medicine in Greenville, North Carolina. Dr. Qadir is highly rated in 37 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Pleuropulmonary Blastoma, Small Cell Lung Cancer (SCLC), Colorectal Cancer, and Endoscopy.

Frequently Asked Questions about Dr. Peter Watson

How do I make an appointment with Dr. Peter Watson?

You can book an appointment with Dr. Peter Watson by calling their office at 252-559-2200. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Peter Watson a top-rated expert for Angiosarcoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Peter Watson is classified as an Distinguished expert for Angiosarcoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Peter Watson specialize in?

While Dr. Peter Watson is a Oncology, they have specific expertise in Angiosarcoma, Inflammatory Breast Cancer, and Lung Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Peter Watson participate in research or clinical trials?

Yes. Dr. Peter Watson has published 3 articles and abstracts on conditions like Angiosarcoma. You can view a list of Dr. Peter Watson's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Peter Watson accept my insurance?

Dr. Peter Watson accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 252-559-2200 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Watson's expertise for a condition
ConditionClose
    View All 8 Distinguished Conditions
    View All 16 Advanced Conditions
    View All 58 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile